S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
STLN · Starling Oncology, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Oncology Institute Inc (STLN)
NASDAQ NMS - GLOBAL MARKET
Health Care
$6.83
+0.20
(+3.01%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$6.83
$6.64
$6.95
52-WEEK RANGE
$6.83
$4.85
$7.13
What's happening
- STLN is up 3.01% today, trading at $6.83. — Live quote
- Volume today (108,294) is well below its 3-month average of 1,385,060. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.08 actual vs. $-0.07 estimated (-22.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
STLN
+28.24%
vs S&P 500
+28.54%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.08
Est. $-0.07
MISS -22.5%
2026-04-26 (Q1 2026)
$-0.02
Est. $-0.08
BEAT +74.7%
2026-01-26 (Q4 2025)
$-0.06
Est. $-0.09
BEAT +34.6%
2025-10-26 (Q3 2025)
$-0.14
Est. $-0.12
MISS -21.1%
Valuation Measures & Ratios
Enterprise Value4—
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1.12
Price / Book7129.59
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-6.18%
Operating Margin-4.44%
Return on Equity (ROE8)-482.58%
Return on Assets (ROA9)-21.52%
Avg Volume (3M)1,385,060
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $665.7M | $383.8M | $413.2M | $233.0M | $104.0M |
| P/E | -14.54 | -6.90 | -5.97 | -3.42 | -1.46 |
| Price/Sales | 1.18 | 0.76 | 0.90 | 0.55 | 0.26 |
| Price/Book | -26.72 | -23.57 | -33.66 | -25.93 | 20.51 |
| EV/Revenue | 1.32 | 0.91 | 1.06 | 0.73 | 0.45 |
| EV/EBITDA | -31.84 | -16.08 | -13.54 | — | — |
| ROE | 183.81% | 341.36% | 563.88% | 758.89% | -1401.97% |
| ROA | -25.69% | -33.04% | -42.30% | -42.67% | -43.33% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,793,070
Change from Prior Settlement-3.70%
% of Float—
Days to Cover (Short Ratio)4.31
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 34.6% on the provider's reported measure. Finnhub fundamentals ↗
Potential concerns
- Net profit margin is -6.2%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on STLN
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $161.3M | $147.4M | $136.6M | $119.8M | $104.4M | $99.9M | $98.6M | $94.7M |
| Operating income | -$4.6M | -$6.5M | -$8.1M | -$11.2M | -$9.9M | -$13.9M | -$16.4M | -$18.0M |
| Net income | -$9.8M | -$2.5M | -$16.5M | -$17.0M | -$19.6M | -$16.1M | -$15.5M | -$19.9M |
| EPS (diluted) | $-0.08 | $-0.02 | $-0.14 | $-0.15 | $-0.21 | $-0.18 | $-0.17 | $-0.22 |
| EPS (basic) | $-0.08 | $-0.02 | $-0.14 | $-0.15 | $-0.21 | $-0.18 | $-0.17 | $-0.22 |
| Operating margin | -$3 | -$4 | -$6 | -$9 | -$9 | -$14 | -$17 | -$19 |
| Net margin | -$6 | -$2 | -$12 | -$14 | -$19 | -$16 | -$16 | -$21 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $178.2M | $168.2M | $164.7M | $163.6M | $159.8M | $164.0M | $172.7M | $179.2M |
| Total liabilities | $203.1M | $184.5M | $180.4M | $175.9M | $168.8M | $158.9M | $169.1M | $163.7M |
| Stockholders' equity | -$24.9M | -$16.3M | -$15.7M | -$12.3M | -$9.0M | $5.1M | $3.6M | $15.5M |
| Total current assets | $129.0M | $116.9M | $112.7M | $110.1M | $104.8M | $106.8M | $112.4M | $116.4M |
| Total current liabilities | $94.9M | $79.4M | $71.0M | $65.6M | $64.8M | $59.5M | $52.2M | $46.8M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Marketable securities (current) | — | — | — | — | — | — | $0 | $0 |
| Accounts receivable | $66.3M | $58.1M | $59.0M | $59.6M | $55.7M | $49.3M | $48.3M | $54.5M |
| Inventory | $20.0M | $24.3M | $16.9M | $18.9M | $15.8M | $12.3M | $10.0M | $10.1M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $10.6M | $10.7M | $10.7M | $10.7M | $10.9M | $11.1M | $11.9M | $12.3M |
| Goodwill | $7.2M | $7.2M | $7.2M | $7.2M | $7.2M | $7.2M | $7.2M | $7.2M |
| Intangible assets | $9.6M | $10.3M | $11.0M | $11.7M | $12.4M | $14.0M | $14.8M | $15.6M |
| Other non-current assets | $657.0K | $620.0K | $606.0K | $586.0K | $586.0K | $591.0K | $589.0K | $588.0K |
| Accounts payable | $60.3M | $47.6M | $43.2M | $35.6M | $34.9M | $29.3M | $24.3M | $24.6M |
| Accrued liabilities | $27.4M | $24.3M | $20.6M | $22.8M | $22.9M | $23.4M | $21.1M | $15.4M |
| Deferred revenue (current) | — | — | $2.3M | $4.9M | $5.2M | $4.1M | $2.4M | $1.4M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $27.4M | $24.3M | $20.6M | $22.8M | $22.9M | $23.4M | $21.1M | $15.4M |
| Long-term debt | $79.9M | $78.6M | $77.4M | $76.2M | $75.0M | $73.9M | $93.1M | $91.5M |
| Other non-current liabilities | $30.0K | $19.0K | $28.0K | $3.0K | $10.0K | $117.0K | $125.0K | $133.0K |
| Common stock & paid-in capital | $10.0K | $10.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K |
| Retained earnings | -$283.7M | -$273.9M | -$271.4M | -$263.9M | -$247.4M | -$230.4M | -$210.8M | -$197.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.9M | -$2.2M | $3.2M | -$12.6M | -$10.2M | -$5.0M | $4.2M | $819.0K |
| Investing cash flow | -$908.0K | -$1.0M | -$1.1M | -$604.0K | -$1.2M | -$202.0K | -$1.8M | $10.4M |
| Financing cash flow | -$218.0K | -$28.0K | $3.7M | $10.6M | $2.0M | -$4.7M | -$164.0K | -$243.0K |
| Free cash flow | $11.0M | -$3.3M | $2.2M | -$13.2M | -$11.4M | -$5.3M | $2.4M | $1.2M |
| Capital expenditures | $908.0K | $1.0M | $1.1M | $604.0K | $1.2M | $328.0K | $1.8M | -$402.0K |
| Depreciation & amortization | $1.8M | $1.6M | $1.6M | $1.7M | $1.8M | $1.8M | $1.7M | $1.6M |
| Share-based compensation | $1.1M | $1.7M | $1.3M | $1.0M | $752.0K | $1.5M | $1.3M | $2.4M |
| Deferred income taxes | $0 | — | $0 | $0 | -$32.0K | — | $0 | $0 |
| Change in accounts receivable | $8.2M | -$864.0K | -$641.0K | $4.0M | $8.0M | $985.0K | -$6.2M | $485.0K |
| Change in inventory | -$4.3M | $7.4M | -$2.0M | $3.1M | $3.5M | $2.3M | -$67.0K | -$1.2M |
| Change in accounts payable | $12.5M | $4.6M | $7.7M | $439.0K | $6.4M | $5.1M | $739.0K | $7.6M |
| Purchases of investments | — | — | — | — | — | — | $0 | $0 |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | $0 | $0 | $0 | $0 | $0 | $20.0M | $0 | $0 |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $502.7M | $393.4M | $324.2M | $252.5M | $203.0M |
| Operating income | -$36.1M | -$60.1M | -$77.0M | -$82.0M | -$45.9M |
| Net income | -$60.6M | -$64.7M | -$83.1M | $152.0K | -$10.9M |
| EPS (diluted) | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 |
| EPS (basic) | $-0.54 | $-0.71 | $-0.92 | $0.00 | $-0.16 |
| Operating margin | -$7 | -$15 | -$24 | -$32 | -$23 |
| Net margin | -$12 | -$16 | -$26 | $0 | -$5 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $164.7M | $172.7M | $209.2M | $261.7M | $203.4M |
| Total liabilities | $180.4M | $169.1M | $152.2M | $138.5M | $99.3M |
| Stockholders' equity | -$15.7M | $3.6M | $57.0M | $123.2M | $104.2M |
| Total current assets | $112.7M | $112.4M | $143.5M | $130.4M | $154.1M |
| Total current liabilities | $71.0M | $52.2M | $34.8M | $29.7M | $29.8M |
| Cash & equivalents | — | — | — | — | — |
| Marketable securities (current) | — | $0 | $49.4M | $59.8M | $0 |
| Accounts receivable | $59.0M | $48.3M | $42.4M | $39.8M | $20.0M |
| Inventory | $16.9M | $10.0M | $13.7M | $9.3M | $6.4M |
| Marketable securities (non-current) | — | — | $0 | $58.4M | $0 |
| Property, plant & equipment | $10.7M | $11.9M | $10.9M | $8.5M | $4.2M |
| Goodwill | $7.2M | $7.2M | $7.2M | $21.4M | $26.6M |
| Intangible assets | $11.0M | $14.8M | $17.9M | $18.0M | $18.2M |
| Other non-current assets | $606.0K | $589.0K | $561.0K | $477.0K | $320.0K |
| Accounts payable | $43.2M | $24.3M | $14.4M | $9.4M | $15.6M |
| Accrued liabilities | $20.6M | $21.1M | $14.0M | $14.6M | $13.9M |
| Deferred revenue (current) | $2.3M | $2.4M | $545.0K | $1.1M | $262.0K |
| Short-term debt | — | — | — | $0 | $183.0K |
| Other current liabilities | $20.6M | $21.1M | $14.0M | $14.6M | $13.9M |
| Long-term debt | $77.4M | $93.1M | $86.8M | $80.6M | $0 |
| Other non-current liabilities | $28.0K | $125.0K | $365.0K | $868.0K | $6.9M |
| Common stock & paid-in capital | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K |
| Retained earnings | -$271.4M | -$210.8M | -$146.2M | -$63.1M | -$63.2M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$24.6M | -$26.5M | -$36.3M | -$61.8M | -$32.7M |
| Investing cash flow | -$3.1M | $46.2M | $62.6M | -$131.6M | -$12.2M |
| Financing cash flow | $11.6M | -$3.5M | -$6.8M | $92.2M | $154.0M |
| Free cash flow | -$27.8M | -$30.3M | -$40.9M | -$67.3M | -$35.5M |
| Capital expenditures | $3.2M | $3.8M | $4.6M | $5.5M | $2.8M |
| Depreciation & amortization | $6.9M | $6.3M | $5.9M | $4.4M | $3.3M |
| Share-based compensation | $4.6M | $11.2M | $17.8M | $27.7M | $24.5M |
| Deferred income taxes | -$32.0K | $0 | -$76.0K | -$263.0K | -$1.2M |
| Change in accounts receivable | $12.3M | $6.0M | $4.6M | $20.3M | $2.2M |
| Change in inventory | $6.8M | -$3.6M | $4.4M | $1.7M | $1.8M |
| Change in accounts payable | $19.6M | $9.2M | $5.1M | -$6.2M | $2.9M |
| Purchases of investments | — | $0 | $9.6M | $117.5M | $0 |
| Share repurchases | — | $0 | $1.0M | $9.0M | $0 |
| Debt issued | — | — | $0 | $110.0M | $0 |
| Debt repaid | $20.0M | $0 | — | $0 | $7.2M |
| Tax withholding on stock comp | — | — | $0 | $413.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding STLN as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-14 to 2026-08-21
Recent transactions
- Insiders have net sold 202,256 shares over the last 182 days, across 8 purchases and 4 sales.
- Most recent: Hively Brad (Director) — Open market sale of 298,853 shares on 2026-08-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)143,500 sh(8 txns)
Sales (open market)345,756 sh(4 txns)
Net Shares-202,256
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Hively Brad | Director | Open market sale | 2026-08-21 | 298,853 |
| Chernett Jorey | 10% owner | Open market purchase | 2026-08-14 | 12,000 |
| Kaushal Mohit | Director | Grant / award | 2026-07-27 | 33,133 |
| McGeorge Anne | Director | Grant / award | 2026-07-27 | 41,165 |
| Pacala Mark L | Director | Grant / award | 2026-07-27 | 30,120 |
| STOLPER MARK | Director | Grant / award | 2026-07-27 | 31,124 |
| TZOUMAKAS KIMBERLY JO | Director | Grant / award | 2026-07-27 | 29,116 |
| Johnson Karen Marie | Director | Grant / award | 2026-07-27 | 31,124 |
| Podnos Yale | Chief Medical Officer | Option exercise | 2026-07-14 | 17,974 |
| Virnich Daniel | Chief Executive Officer | Other acquisition/disposition | 2026-05-21 | 23,058 |
| Carter Robert Ross | Chief Financial Officer | Other acquisition/disposition | 2026-05-21 | 1,604 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-21 | Hively Brad | Director | Open market sale | 298,853 | $6.51 |
| 2026-08-14 | Chernett Jorey | 10% owner | Open market purchase | 12,000 | $6.54 |
| 2026-07-27 | Kaushal Mohit | Director | Grant / award | 33,133 | $0.00 |
| 2026-07-27 | McGeorge Anne | Director | Grant / award | 41,165 | $0.00 |
| 2026-07-27 | Pacala Mark L | Director | Grant / award | 30,120 | $0.00 |
| 2026-07-27 | STOLPER MARK | Director | Grant / award | 31,124 | $0.00 |
| 2026-07-27 | TZOUMAKAS KIMBERLY JO | Director | Grant / award | 29,116 | $0.00 |
| 2026-07-27 | Hively Brad | Director | Grant / award | 27,108 | $0.00 |
| 2026-07-27 | Johnson Karen Marie | Director | Grant / award | 31,124 | $0.00 |
| 2026-07-21 | Chernett Jorey | 10% owner | Open market purchase | 18,000 | $5.27 |
| 2026-07-14 | Podnos Yale | Chief Medical Officer | Option exercise | 17,974 | $1.87 |
| 2026-07-14 | Podnos Yale | Chief Medical Officer | Open market sale | 17,974 | $6.43 |
| 2026-07-14 | Podnos Yale | Chief Medical Officer | Option exercise | 5,478 | $2.00 |
| 2026-07-14 | Podnos Yale | Chief Medical Officer | Open market sale | 5,478 | $6.35 |
| 2026-07-10 | Chernett Jorey | 10% owner | Open market purchase | 15,000 | $5.85 |
| 2026-07-07 | TZOUMAKAS KIMBERLY JO | Director | Grant / award | 17,185 | $0.00 |
| 2026-07-07 | STOLPER MARK | Director | Grant / award | 25,833 | $0.00 |
| 2026-06-23 | Chernett Jorey | 10% owner | Open market purchase | 18,000 | $5.02 |
| 2026-06-08 | Podnos Yale | Chief Medical Officer | Open market sale | 23,451 | $5.38 |
| 2026-06-04 | Chernett Jorey | 10% owner | Open market purchase | 12,000 | $4.75 |
| 2026-05-21 | Podnos Yale | Chief Medical Officer | Other acquisition/disposition | 1,805 | $4.47 |
| 2026-05-21 | Virnich Daniel | Chief Executive Officer | Other acquisition/disposition | 23,058 | $4.47 |
| 2026-05-21 | Carter Robert Ross | Chief Financial Officer | Other acquisition/disposition | 1,604 | $4.47 |
| 2026-05-20 | Chernett Jorey | 10% owner | Open market purchase | 33,500 | $4.07 |
| 2026-05-19 | Chernett Jorey | 10% owner | Open market purchase | 5,000 | $4.05 |
| 2026-05-19 | Chernett Jorey | 10% owner | Open market purchase | 30,000 | $4.09 |
| 2026-04-16 | Kaushal Mohit | Director | Open market sale | 38,433 | $3.50 |
| 2026-04-14 | Kaushal Mohit | Director | Open market sale | 57,286 | $3.50 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-02 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-21 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-20 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
Recent news
Headlines about STLN (Starling Oncology, Inc.). Links open the publisher — we don’t host full articles.
-
Starling Oncology (STLN) Stock Forum and Discussion
Moomoo · 2026-10-19 -
STLN Nov 2026 2.000 put (STLN261120P00002000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-19 -
STLN Nov 2026 3.000 call (STLN261120C00003000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-19 -
Behavioral Patterns of STLN and Institutional Flows
Stock Traders Daily · 2026-10-19 -
MKC,JBL,STLN,CHPT,MU,VIRC,XZO,DAL,DELL | stock prices | quote comparison
Yahoo Finance UK · 2026-10-17 -
The Oncology Institute, Inc. (STLN) stock price, news, quote and history
Yahoo Finance UK · 2026-10-17 -
Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views
Yahoo Finance · 2026-10-15 -
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Yahoo Finance · 2026-10-01
No headlines in this category right now — try “All”.